215,137 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP acquired a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 215,137 shares of the company’s stock, valued at approximately $2,726,000.

Several other institutional investors and hedge funds also recently bought and sold shares of DAWN. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $31,000. E Fund Management Co. Ltd. purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $143,000. KLP Kapitalforvaltning AS purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth approximately $150,000. XTX Topco Ltd acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $178,000. Finally, Teacher Retirement System of Texas grew its holdings in shares of Day One Biopharmaceuticals by 20.9% during the 4th quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock valued at $226,000 after acquiring an additional 3,086 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.40. This trade represents a 8.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares in the company, valued at approximately $473,639.92. The trade was a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,064 shares of company stock worth $251,925. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Stock Down 2.8 %

NASDAQ:DAWN opened at $7.02 on Tuesday. The company’s 50 day moving average is $10.01 and its 200-day moving average is $12.33. Day One Biopharmaceuticals, Inc. has a 12 month low of $6.65 and a 12 month high of $18.07. The firm has a market cap of $711.51 million, a price-to-earnings ratio of -6.82 and a beta of -1.24.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million for the quarter, compared to analysts’ expectations of $27.11 million. Research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DAWN has been the subject of a number of research reports. The Goldman Sachs Group reduced their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a research report on Tuesday, March 25th. JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. HC Wainwright reissued a “buy” rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, April 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Buy” and an average target price of $32.29.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.